BPC-157: The Complete Research Guide
Dr. Sieglinde Klaus
Scientific Editorial Team · Bergdorf Bioscience
Table of Contents
- 01What is BPC-157 and where does it come from?
- 02How does BPC-157 work in the body?
- 03What does the research show on tendons and muscles?
- 04What are the findings in the gastrointestinal area?
- 05How does BPC-157 outperform individual growth factors?
- 06What dosage is used in research?
- 07How is BPC-157 stored correctly?
- 08Frequently asked questions
- Is BPC-157 a natural peptide?
- Why do most studies come from Zagreb?
- Can BPC-157 be taken orally?
- What side effects are known?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids with the sequence GEPPPGKPADDAGLV and a molecular weight of 1419 Da. Originally isolated from a gastric protective protein, it shows regenerative properties in tendons, muscles, the gastrointestinal tract and the vascular system across more than 100 studies. Lead researcher Prof. Predrag Sikiric of the University of Zagreb has largely built the body of evidence (Sikiric, 1999).
What is BPC-157 and where does it come from?
BPC-157 is a stable pentadecapeptide isolated from a protective protein found in gastric juice. Its 15-amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val is unique in nature - no other known protein contains this exact arrangement. Its exceptional stability is notable: BPC-157 remains stable in human gastric juice for over 24 hours, whereas most peptides are degraded within minutes (Sikiric et al., 2011). In toxicological studies, no lethal dose (LD1) could be determined - an indication of an exceptionally broad safety profile. The peptide was designated PL 14736 (also PL-10) for clinical IBD studies (inflammatory bowel disease).
How does BPC-157 work in the body?
BPC-157 exerts its effects through several signaling pathways at once. Central to this is modulation of the nitric oxide (NO) system: BPC-157 influences NO synthesis via multiple pathways and retains its efficacy even when NO production is inhibited (Klicek et al., 2008). A second key mechanism is vascular recruitment: after an injury, BPC-157 activates blood vessels that effectively „run toward“ the defect. When a vessel is occluded, alternative vascular routes are activated that bypass the defect and enable collateral supply (Sikiric et al., 2018). In addition, BPC-157 promotes the expression of VEGF (Vascular Endothelial Growth Factor) and supports collagen synthesis.
What does the research show on tendons and muscles?
Tendon research provides some of the most compelling results. In a study on Achilles tendon detachment in rats, BPC-157 improved healing functionally, biomechanically and microscopically: load-bearing capacity, stiffness and Young's modulus rose significantly, and collagen fiber organization was markedly improved with increased type I collagen (Cerovecki et al., 2006). Particularly notable: methylprednisolone worsened healing, yet BPC-157 substantially reduced this corticosteroid-induced impairment. Independently, a Taiwanese research group confirmed that BPC-157 accelerates tendon outgrowth, increases cell survival under oxidative stress and boosts fibroblast migration in a dose-dependent manner via the FAK-paxillin signaling pathway (Chang et al., 2011).
What are the findings in the gastrointestinal area?
In the GI tract, BPC-157 shows its strongest and best-documented effects. In the earliest comparative study, BPC-157 was the only peptide consistently effective across all ulcer models tested (restraint stress, cysteamine, 96% ethanol), outperforming H2-receptor antagonists, dopamine promoters and other gut peptides (Sikiric et al., 1994). The effect spans the entire GI tract: esophagus, stomach, duodenum, intestine, liver and pancreas. Clinically, BPC-157 was designated PL 14736 for IBD studies, underscoring the translational relevance of the preclinical data.
How does BPC-157 outperform individual growth factors?
A decisive advantage over established growth factors such as EGF, FGF and VEGF is the universal efficacy of BPC-157 across different tissue types. While individual growth factors typically require specific conditions or tissues, BPC-157 alone was consistently effective in all models of acute and chronic injury throughout the entire GI tract (Seiwerth et al., 2018). The same dosing protocols that are effective in the GI area also show positive results in tendon, ligament, muscle and bone models. This cross-tissue efficacy with a unified angiogenic mechanism is unique among research peptides.
What dosage is used in research?
In preclinical research, 250 to 500 micrograms (mcg) are typically administered subcutaneously once or twice daily. The half-life is approximately 4 to 6 hours. The extremely broad safety profile is notable: no study has been able to determine a lethal dose (LD1), making BPC-157 one of the best-tolerated research peptides. BPC-157 from Bergdorf Bioscience contains 5mg of lyophilized peptide per vial with ≥99% HPLC-verified purity. Available as a single pack (€66.99), 2-pack (€127.28) or 3-pack (€180.87).
How is BPC-157 stored correctly?
Lyophilized BPC-157 should be stored refrigerated at 2-8°C. For long-term storage, -20°C is recommended, where stability is maintained for over 2 years. After reconstitution with bacteriostatic water, keep refrigerated and use within 4 weeks. Avoid repeated freeze-thaw cycles. Stored protected from light, BPC-157 retains its integrity throughout the intended shelf life.
Frequently asked questions
Is BPC-157 a natural peptide?
BPC-157 is based on a sequence from a naturally occurring gastric protective protein, but is produced synthetically via SPPS. The exact 15-AA sequence does not occur freely in nature in this form.
Why do most studies come from Zagreb?
Prof. Predrag Sikiric of the University of Zagreb has been studying BPC-157 systematically since the 1990s. Independent confirmations come, among others, from Taiwan (Chang et al., 2011) and several international research groups.
Can BPC-157 be taken orally?
BPC-157 is stable in gastric juice for over 24 hours, which sets it apart from most peptides. In research, both oral and subcutaneous routes of administration are being investigated.
What side effects are known?
In preclinical studies, no significant side effects or a lethal dose could be determined. Larger-scale clinical human studies are still pending.
For research purposes only. Not for human consumption.
Scientific editorial: Dr. Sieglinde Klaus – Bergdorf Bioscience
References
- Sikiric P.. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. 1999.DOI
- Sikiric P., et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sciences. 1994.DOI
- Sikiric P., et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design. 2011.DOI
- Sikiric P., et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Current Pharmaceutical Design. 2018.DOI
- Klicek R., et al. Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System. Journal of Pharmacological Sciences. 2008.